Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

YANG Chunsong; LIU Jianing; LIU Zheng; ZENG Linan; WU Jin; ZHANG Lingli

doi:10.6039/j.issn.1001-0408.2025.01.13

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

更新时间：2025-09-25

- Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty
- ZHONGGUO YAOFANG Vol. 36, Issue 1, Pages: 79-85(2025)
- 作者机构：
  
  1.四川大学华西第二医院药学部，成都　610041
  2.四川大学华西第二医院循证药学中心，成都　610041
  3.国家药品监督管理局药物制剂体内外相关性技术研究重点实验室，成都　610041
  4.出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
  5.四川大学华西临床医学院，成都　610041
  6.四川大学华西第二医院儿科，成都　610041
  7.四川大学转化医学中心分子转化医学实验室，成都　610041
  8.四川大学华西医院中国循证医学中心，成都　610041
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.01.13
  CLC： R956;R977.1
- Received：16 May 2024，
  
  Revised：2024-12-26，
  
  Accepted：27 December 2024，
  
  Published：15 January 2025
- 稿件说明：
移动端阅览
杨春松,刘佳宁,刘峥,等.促性腺激素释放激素类似物联合重组人生长激素治疗中枢性性早熟的成本-效果分析[J].中国药房,2025,36(01):79-85.

YANG Chunsong,LIU Jianing,LIU Zheng,et al.Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty[J].ZHONGGUO YAOFANG,2025,36(01):79-85.
杨春松,刘佳宁,刘峥,等.促性腺激素释放激素类似物联合重组人生长激素治疗中枢性性早熟的成本-效果分析[J].中国药房,2025,36(01):79-85. DOI： 10.6039/j.issn.1001-0408.2025.01.13.

YANG Chunsong,LIU Jianing,LIU Zheng,et al.Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty[J].ZHONGGUO YAOFANG,2025,36(01):79-85. DOI： 10.6039/j.issn.1001-0408.2025.01.13.

摘要

目的

比较促性腺激素释放激素类似物（GnRHa）联合重组人生长激素（rhGH）（联用方案）和GnRHa单药（单用方案）治疗中枢性性早熟（CPP）的长期经济性。

方法

从全社会角度出发，基于四川大学华西第二医院开展的真实世界研究，以终身高为效果指标，以2022年我国农村及城镇居民人均可支配收入（20 133～49 283元）作为社会意愿支付（WTP）阈值，采用成本-效果分析法比较上述两种药物方案治疗CPP女孩的长期经济性。采用单因素敏感性分析和概率敏感性分析验证基础分析结果的稳健性，并通过情境分析比较不同长效制剂组合方案的经济性。

结果

基础分析结果显示，与单用方案相比，采用联用方案每增加CPP女孩1 cm终身高需多花费25 193.49元；联用方案对于农村地区居民不具有经济性，但对于城镇地区居民具有经济性。单因素敏感性分析结果显示，对基础分析结果可能产生影响的不确定因素主要为rhGH价格、联用方案组患儿终身高、联用方案组rhGH治疗时间、单用方案组患儿终身高。概率敏感性分析结果显示，当WTP阈值大于26 010元/cm时，联用方案具有经济性的概率均高于单用方案。情境分析结果显示，当使用GnRHa长效制剂时，每3个月肌内注射1次的联用方案对于农村地区居民不具有经济性，但对于城镇地区居民具有经济性；当使用rhGH长效制剂时，每周皮下注射1次的联用方案对于农村地区和城镇地区居民均不具有经济性。

结论

推荐家庭经济负担能力相对较强的CPP患儿在GnRHa治疗的基础上额外联用rhGH来改善终身高；应考虑治疗的获益、风险和可负担性，避免盲目追求身高增长而滥用rhGH。

Abstract

OBJECTIVE

To compare the long-term cost-effectiveness of gonadotrophin-releasing hormone analogue （GnRHa） combined with recombinant human growth hormone （rhGH）（combination therapy regimen） versus GnRHa monotherapy （monotherapy regimen） in the treatment of central precocious puberty （CPP）.

METHODS

From the societal perspective and based on a real-world study conducted at West China Second Hospital of Sichuan University， the cost-effectiveness analysis was performed to compare the long-term cost-effectiveness of two pharmacotherapy regimens for CPP girls， with final height as outcome indexes， using per capita disposable income of rural residents and urban residents （20 133-49 283 yuan） in 2022 as the social willing-to-pay （WTP） threshold. The robustness of the basic analysis result was verified by using one-way sensitivity analysis and probability sensitivity analysis， and the cost-effectiveness of different combinations of long-acting preparations was compared using scenario analysis.

RESULTS

The basic analysis result showed that the combination therapy regimen required an additional cost of 25 193.49 yuan for every one-centimeter improvement in the final height of girls with CPP compared with the monotherapy regimen， which was not cost-effective for residents in rural areas， but it was cost-effective for residents in urban areas. One-way sensitivity analysis showed that the uncertain factors with potential impacts on the results were， in order， the price of rhGH， the final height of pediatric patients in the combination therapy regimen group， the course of rhGH in the combination therapy regimen group， and the final height of pediatric patients in the monotherapy regimen group. Probabilistic sensitivity analysis indicated that the probability of the combination therapy regimen being cost-effective was higher than that of the monotherapy regimen when WTP was more than 26 010 yuan/cm. When GnRHa long-acting preparation was used for intramuscular injection every 3 months， the combination therapy regimen was not cost-effective for rural residents， but was cost-effective for urban residents； when rhGH long-acting preparation was injected subcutaneously once a week， the combination therapy regimen was not cost-effective for residents in both rural areas and urban areas.

CONCLUSIONS

The combination of GnRHa and rhGH is only recommended for CPP children with better affordability to improve final height. The benefits， risks， and affordability of treatment should be comprehensively considered before the decisions on pharmacotherapy， to avoid abuse of rhGH due to the blind pursuit of height growth.

关键词

Keywords

references

CHEUICHE A V ， DA SILVEIRA L G ， DE PAULA L C P ， et al . Diagnosis and management of precocious sexual maturation：an updated review [J ] . Eur J Pediatr ， 2021 ， 180 （ 10 ）： 3073 - 3087 .

TEILMANN G ， PEDERSEN C B ， JENSEN T K ， et al . Prevalence and incidence of precocious pubertal development in Denmark：an epidemiologic study based on national registries [J ] . Pediatrics ， 2005 ， 116 （ 6 ）： 1323 - 1328 .

KIM Y J ， KWON A ， JUNG M K ， et al . Incidence and prevalence of central precocious puberty in Korea：an epidemiologic study based on a national database [J ] . J Pediatr ， 2019 ， 208 ： 221 - 228 .

BRÄUNER E V ， BUSCH A S ， ECKERT-LIND C ， et al . Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark，1998 to 2017 [J ] . JAMA Netw Open ， 2020 ， 3 （ 10 ）： e2015665 .

KANG S ， PARK M J ， KIM J M ， et al . Ongoing increasing trends in central precocious puberty incidence among Korean boys and girls from 2008 to 2020 [J ] . PLoS One ， 2023 ， 18 （ 3 ）： e0283510 .

ECKERT-LIND C ， BUSCH A S ， PETERSEN J H ， et al . Worldwide secular trends in age at pubertal onset assessed by breast development among girls：a systematic review and meta-analysis [J ] . JAMA Pediatr ， 2020 ， 174 （ 4 ）： e195881 .

LI H M ， YU G ， DUAN H L ， et al . Changes in children’s healthcare visits during coronavirus disease-2019 pandemic in Hangzhou，China [J ] . J Pediatr ， 2020 ， 224 ： 146 - 149 .

中华医学会儿科学分会内分泌遗传代谢学组，中华儿科杂志编辑委员会 . 中枢性性早熟诊断与治疗专家共识：2022 [J ] . 中华儿科杂志， 2023 ， 61 （ 1 ）： 16 - 22 .

Chinese Society of Pediatric Endocrinology and Metabolism ， Editorial Committee of Chinese Journal of Pediatrics . Expert consensus on the diagnosis and treatment of central precocious puberty：2022 [J ] . Chin J Pediatr ， 2023 ， 61 （ 1 ）： 16 - 22 .

秦淼，曹旺，郑蕾，等 . 不同促性腺激素释放激素类似物治疗中枢性性早熟患儿的药物经济学评价 [J ] . 中国药物经济学， 2021 ， 16 （ 11 ）： 10 - 14，24 .

QIN M ， CAO W ， ZHENG L ， et al . Pharmacoeconomic evaluation of different gonadotropin releasing hormone analogs in the treatment of children with central precocious puberty [J ] . China J Pharm Econ ， 2021 ， 16 （ 11 ）： 10 - 14，24 .

药智网 . 2022年省级药品采购中标价格 [EB/OL ] .（ 2022-12-30 ）[ 2023-09-01 ] . https：//db.yaozh.com/ https://db.yaozh.com/ .

Yaozhi Network . 2022 Provincial drug procurement winning prices [EB/OL ] .（ 2022-12-30 ）[ 2023-09-01 ] . https：//db.yaozh.com/ https://db.yaozh.com/ .

北京市医疗保障局 . 北京市医疗保障局、北京市卫生健康委员会、北京市人力资源和社会保障局关于规范调整部分医疗服务价格项目的通知 [EB/OL ] .（ 2022-02-21 ）[ 2023-09-01 ] . https：//www.beijing.gov.cn/zhengce/zhengcefagui/202202/t20220222_2614060.html https://www.beijing.gov.cn/zhengce/zhengcefagui/202202/t20220222_2614060.html .

Beijing Municipal Medical Security Bureau . Beijing Municipal Medical Security Bureau，Beijing Municipal Health Commission，Beijing Municipal Human Resources and Social Security Bureau on the notice of standardizing and adjusting some medical service price items [EB/OL ] .（ 2022-02-21 ）[ 2023-09-01 ] . https：//www.beijing.gov.cn/zhengce/zhengcefagui/202202/t20220222_2614060.html https://www.beijing.gov.cn/zhengce/zhengcefagui/202202/t20220222_2614060.html .

广州市医疗保障局 . 广州市医疗保障局、广州市财政局、广州市卫生健康委员会关于实施《广东省基本医疗服务价格项目目录（2021年版）》和《广东省市场调节价医疗服务价格项目目录（2021年版）》的通知 [EB/OL ] .（ 2021-08-10 ）[ 2023-09-01 ] . https：//www.gz.gov.cn/gzybj/gkmlpt/content/7/7623/post_7623885.html#14462 https://www.gz.gov.cn/gzybj/gkmlpt/content/7/7623/post_7623885.html#14462 .

Guangzhou Municipal Medical Security Bureau . Guangzhou Municipal Medical Security Bureau，Guangzhou Municipal Finance Bureau，Guangzhou Municipal Health Commission on the implementation of Guangdong Province Basic Medical Service Price Item Catalog （ 2021 Edition ） and Guangdong Province Market-Regulated Medical Service Price Item Catalog （ 2021 Edition ） [EB/OL ] .（ 2021-08-10 ）[ 2023-09-01 ] . https：//www.gz.gov.cn/gzybj/gkmlpt/content/7/7623/post_7623885.html#14462 https://www.gz.gov.cn/gzybj/gkmlpt/content/7/7623/post_7623885.html#14462 .

江苏省医疗保障局 . 关于《江苏省医疗服务价格项目目录（2022版）》的公示 [EB/OL ] .（ 2023-01-04 ）[ 2023-09-01 ] . https：//ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html https://ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html .

Jiangsu Provincial Medical Security Bureau . Public notice on Jiangsu Province Medical Service Price Item Catalog （ 2022 Edition ） [EB/OL ] .（ 2023-01-04 ）[ 2023-09-01 ] . https：//ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_1071-8184.html https://ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_1071-8184.html .

四川省医疗保障局 . 四川省医疗保障局关于公布四川省2021年第一批新增和修订医疗服务价格项目的通知 [EB/OL ] .（ 2021-05-18 ）[ 2023-09-01 ] . https：//ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html https://ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html .

Sichuan Provincial Medical Security Bureau . Sichuan Provincial Medical Security Bureau on the announcement of the first batch of new and revised medical service price items in Sichuan Province for 2021 [EB/OL ] .（ 2021-05-18 ）[ 2023-09-01 ] . https：//ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html https://ybj.jiangsu.gov.cn/art/2023/1/4/art_73935_10718184.html .

武汉市医疗保障局 . 公立医疗机构医疗服务项目价格 [EB/OL ] .（ 2022-10-19 ）[ 2023-09-01 ] . https：//ybj.wuhan.gov.cn/bsfw/yyfwjgyzbcg/202210/t20221019_2062445.shtml https://ybj.wuhan.gov.cn/bsfw/yyfwjgyzbcg/202210/t20221019_2062445.shtml .

Wuhan Municipal Medical Security Bureau . Public medical institutions medical service project prices [EB/OL ] .（ 2022-10-19 ）[ 2023-09-01 ] . https：//ybj.wuhan.gov.cn/bsfw/yyfwjgyzbcg/202210/t20221019_2062445.shtml https://ybj.wuhan.gov.cn/bsfw/yyfwjgyzbcg/202210/t20221019_2062445.shtml .

国家卫生健康委办公厅 . 国家卫生健康委办公厅关于2021年度全国三级公立医院绩效考核国家监测分析情况的通报 [EB/OL ] .（ 2022-12-21 ）[ 2023-09-01 ] . http：//www.nhc.gov.cn/yzygj/s3594q/202212/f40bfe4606eb4b1-d8e7c82b1473df9ae.shtml http://www.nhc.gov.cn/yzygj/s3594q/202212/f40bfe4606eb4b1-d8e7c82b1473df9ae.shtml .

National Health Commission Office . National Health Commission Office on the notification of the national monitoring and analysis of the performance assessment of national tertiary public hospitals in 2021 [EB/OL ] .（ 2022-12-21 ）[ 2023-09-01 ] . http：//www.nhc.gov.cn/yzygj/s3594q/202212/f40bfe4606eb4b1d8e7c82b1473df9ae.shtml http://www.nhc.gov.cn/yzygj/s3594q/202212/f40bfe4606eb4b1d8e7c82b1473df9ae.shtml .

艾媒餐饮研究院 . 2022年中国餐饮行业发展现状及市场调研分析报告 [EB/OL ] .（ 2022-04-19 ）[ 2023-09-01 ] . https：//www.iimedia.cn/c400/84947.html https://www.iimedia.cn/c400/84947.html .

iMedia Catering Research Institute . 2022 China catering industry development status and market research analysis report [EB/OL ] .（ 2022-04-19 ）[ 2023-09-01 ] . https：//www.iimedia.cn/c400/84947.html https://www.iimedia.cn/c400/84947.html .

财政部 . 关于印发《中央和国家机关差旅费管理办法》的通知 [EB/OL ] .（ 2013-12-31 ）[ 2023-09-01 ] . https：//www.gov.cn/zwgk/2014-01/07/content_2561017.htm https://www.gov.cn/zwgk/2014-01/07/content_2561017.htm .

Ministry of Finance . Notice on issuing Central and State Organs Travel Expense Management Measures [EB/OL ] .（ 2013-12-31 ）[ 2023-09-01 ] . https：//www.gov.cn/zwgk/2014-01/07/content_2561017.htm https://www.gov.cn/zwgk/2014-01/07/content_2561017.htm .

国家统计局 . 2022年居民收入和消费支出情况 [EB/OL ] .（ 2023-01-17 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202302/t20230203_1901715.html https://www.stats.gov.cn/sj/zxfb/202302/t20230203_1901715.html .

National Bureau of Statistics . 2022 resident income and consumption expenditure situation [EB/OL ] .（ 2023-01-17 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202302/t20230203_1901715.html https://www.stats.gov.cn/sj/zxfb/202302/t20230203_1901715.html .

旅智科技 . 2022年度中国住宿业数据发展报告 [EB/OL ] .（ 2023-01-17 ）[ 2023-09-01 ] . https：//hub.traveldaily.cn/report/323 https://hub.traveldaily.cn/report/323 .

Lvzhi Technology . 2022 China accommodation industry data development report [EB/OL ] .（ 2023-01-17 ）[ 2023-09-01 ] . https：//hub.traveldaily.cn/report/323 https://hub.traveldaily.cn/report/323 .

国家统计局 . 中华人民共和国2022年国民经济和社会发展统计公报 [EB/OL ] .（ 2023-02-28 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html https://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html .

National Bureau of Statistics . The People’s Republic of China 2022 national economic and social development statistical bulletin [EB/OL ] .（ 2023-02-28 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html https://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html .

国家统计局 . 2022年城镇非私营单位就业人员年平均工资 114 029 元[EB/OL ] .（ 2023-05-09 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202305/t20230509_1939-290.html https://www.stats.gov.cn/sj/zxfb/202305/t20230509_1939-290.html .

National Bureau of Statistics . Average annual wages of employees in urban non-private units in 2022 was 114 029 yuan[EB/OL ] .（ 2023-05-09 ）[ 2023-09-01 ] . https：//www.stats.gov.cn/sj/zxfb/202305/t20230509_1939290.html https://www.stats.gov.cn/sj/zxfb/202305/t20230509_1939290.html .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 178 - 179 .

LIU G E . Guidelines for pharmacoeconomic evaluation in China 2020 [M ] . Beijing ： China Market Press ， 2020 ： 178 - 179 .

CHUNG L Y ， KANG E ， NAM H K ， et al . Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center [J ] . J Korean Med Sci ， 2021 ， 36 （ 34 ）： e219 .

Views

185

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Related Author

WANG Xianying

LIANG Miao

LIU Yang

LIU Guoqiang

GAO Ning

FENG Bing

GAO Shengnan

ZHANG Yuxi

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Society for Integrated Drug and Health Technology Assessment

Dept.of Pharmacy， North China University of Science and Technology Affiliated Hospital

Dept. of Clinical Nutrition， North China University of Science and Technology Affiliated Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰